Educational content. This article does not provide dosing, sourcing or buying information. It explains health risks so readers can make safer decisions and recognise when someone needs help.
New psychoactive substances (NPS) are still appearing in Europe at a rate of roughly one a week. In 2025 alone, 50 substances were reported for the first time, and the European Union Drugs Agency (EUDA) now monitors more than 1,000 of them. This article explains how the EU spots these substances, decides which ones are harmful enough to control, and how that decision becomes law in each member state. It is a factual overview, not legal advice.
What counts as a new psychoactive substance?
In EU law, a new psychoactive substance is a substance that is not controlled under the two main UN drug treaties – the 1961 Single Convention and the 1971 Convention on Psychotropic Substances – but that may pose health or social risks comparable to substances that are. In practice this covers synthetic cathinones, synthetic cannabinoids, designer benzodiazepines, new synthetic opioids such as nitazenes, and many more. Our explainer on what designer drugs and new psychoactive substances are covers the main families in more detail.
The legal framework
The current EU system rests on two instruments adopted in 2017 – a Regulation and a Directive – which have applied since November 2018. They replaced an older, slower procedure from 2005. In July 2024 the former European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) became the European Union Drugs Agency with a stronger mandate, including threat assessments and a European Drug Alert System for rapid warnings.
The key idea is a shared, evidence-based process: substances are detected and assessed once at EU level, and if they are found to be harmful, every member state must control them.
Step by step: from detection to control
1. Early warning
Forensic laboratories, customs, police, hospitals and poison centres in each country report unusual substances to their national focal point, which passes the information to the EU Early Warning System run by the EUDA, alongside Europol. This network is how a newly detected opioid in one country can trigger alerts across Europe within days.
2. Initial report
If a substance raises concern – for example because it is linked to poisonings or deaths, or is spreading quickly – the EUDA, working with Europol, can prepare an initial report summarising what is known about its chemistry, effects, harms and the market.
3. Risk assessment
Where the initial report suggests serious risks, an expert scientific committee carries out a formal risk assessment. It looks at health risks (acute toxicity, dependence, deaths), social risks, and the involvement of organised crime.
4. Commission decision
Based on the risk assessment, the European Commission can adopt a legal act adding the substance to the EU definition of a “drug”. The European Parliament and Council can object within a set period.
5. National law
Member states then have six months to bring the substance under their national drug laws, with criminal penalties for supply.
Examples of EU-level control
- Synthetic cathinones: In 2022 the EU moved to control 3-MMC and 3-CMC across all member states after risk assessments. Further cathinones, including 2-MMC, have since been risk assessed.
- New synthetic opioids: The EUDA reports that it is actively assessing several potent opioids, including newer “orphine” substances, following deaths across Europe. See our guide to nitazenes.
- UN-level control: When a substance is placed under the UN conventions – as HHC was, with effect from December 2025 – all EU states are bound by that international control too.
EU control versus national laws
EU rules set a common floor, not a ceiling. Many countries go much further with generic or blanket laws that cover whole chemical families or any psychoactive substance:
- United Kingdom (no longer in the EU): the Psychoactive Substances Act 2016 bans the supply of almost any psychoactive substance.
- Germany: the NpSG controls entire substance groups and is updated regularly.
- Netherlands: Dutch law has moved towards banning groups of substances rather than individual ones – see our article on whether research chemicals are legal in the Netherlands.
Penalties, and whether personal possession is an offence, are decided nationally. The US uses a different model altogether, described in our article on the US Federal Analogue Act.
Why a ban does not make the market safer
When one substance is controlled, a slightly modified replacement often appears. Each replacement has even less research behind it. For people who use drugs, this means:
- Products may contain a different substance from the one on the label.
- Potency can vary widely between batches.
- Highly potent opioids or benzodiazepines have been found in products sold as something else.
- Doctors may not recognise a new substance, which can delay treatment.
Emergency warning signs
- Unresponsiveness or being impossible to wake
- Slow, shallow or noisy breathing, or blue lips
- Seizures
- Chest pain, very fast heartbeat or overheating
- Severe confusion, agitation or panic
What to do: call 112 (EU), 999 (UK) or 911 (US). If the person is breathing but unresponsive, put them in the recovery position and stay with them. Tell paramedics everything you know about what was taken.
Getting help
- Netherlands: Drugs Infolijn (Trimbos Institute); DIMS drug-checking services across the country.
- UK: FRANK, 0300 123 6600.
- US: SAMHSA National Helpline, 1-800-662-4357.
Related reading
- What are “research chemicals”? The truth behind the label
- Germany’s NpSG explained
- The UK Psychoactive Substances Act 2016 explained
- Synthetic opioids beyond fentanyl
FAQ
Does the EU ban every new psychoactive substance automatically?
No. Only substances that go through the risk-assessment process and are then added by a Commission decision are controlled at EU level. Many others are controlled by national generic laws instead.
How long does EU control take?
It varies. Detection and alerts can happen within days, but a full risk assessment and legal decision take months, and countries then have up to six months to implement it.
Who runs the EU Early Warning System?
The European Union Drugs Agency (EUDA), based in Lisbon, together with Europol and a network of national focal points in each member state.
This article is for general information and is not medical advice. If you are worried about your own or someone else’s drug use, speak to a doctor or one of the services listed above.